| FOpre ≤ 2.5 L (L group) | FOpre > 2.5 L (H group) | P |
---|---|---|---|
N | 31 | 38 | Â |
FO [L] | 1.1 (0.55, 1.6) | 3.4 (2.8, 4.4) | <0.001 |
FO/ECW% | 7.0 (3.6, 9.3) | 17.7 (15.7, 25.3) | <0.001 |
Diabetes | 11 | 8 | 0.2 |
Age [years] | 65 (50,75) | 69 (60, 75) | 0.2 |
Gender [m/f] | 18/13 | 27/11 | 0.3 |
Dialysis vintage [years] | 4 (2, 7) | 7 (5, 11) | 0.02 |
Patients with residual renal function | 0 | 1 | 0.9 |
Treatment time [min] | 236 (233, 241) | 237 (234, 241) | 0.5 |
UFR [L/hr] | 0.67 (0.47, 0.84) | 0.81 (0.56, 0.9) | 0.2 |
UFR [ml/kg BW/h] | 9.5 (5.9, 10.9) | 10.9 (8.0, 13.6) | 0.1 |
Dry body weight [kg] | 74.2 (61.6, 78.6) | 68.4 (61.0, 74.5) | 0.2 |
BMI | 26.4 (23.5, 28.8) | 24.3 (21.6, 26.7) | 0.2 |
Treatment modality [HDF-OL/HD/HFD/HF] | 3/26/2/0 | 6/27/3/2 | 0.6 |
HD related episodes (cramps, dizziness, hypotension) | 5 | 6 | 0.9 |
Left ventricular hypertrophy | 21 | 25 | 0.9 |
Peripheral vascular disease | 17 | 12 | 0.8 |
Coronary heart disease | 10 | 11 | 0.2 |
Hypertension | 31 | 36 | 0.5 |
β-blockers | 10 | 14 | 0.8 |
ACE inhibitors | 9 | 11 | 0.8 |
Calcium antagonist | 14 | 16 | 0.9 |